CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Pict… Read more
CorMedix Inc (CRMD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.082x
Based on the latest financial reports, CorMedix Inc (CRMD) has a cash flow conversion efficiency ratio of 0.082x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.86 Million) by net assets ($374.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CorMedix Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how CorMedix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CorMedix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CorMedix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guanhao Biotech Co Ltd
SHE:300238
|
0.027x |
|
Time Technoplast Limited
NSE:TIMETECHNO
|
0.087x |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
0.057x |
|
Global Medical REIT Inc.
NYSE:GMRE
|
0.035x |
|
Guangzhou Guangri Stock Co Ltd
SHG:600894
|
0.014x |
|
i3 Verticals Inc
NASDAQ:IIIV
|
0.029x |
|
Flaircomm Microelectronics Inc Ordinary Shares - Class A
SHE:301600
|
N/A |
|
Greenvolt Energias Renovaveis SA
LS:GVOLT
|
-0.020x |
Annual Cash Flow Conversion Efficiency for CorMedix Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of CorMedix Inc from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $84.66 Million | $-50.61 Million | -0.598x | -9.18% |
| 2023-12-31 | $70.14 Million | $-38.41 Million | -0.548x | -23.79% |
| 2022-12-31 | $55.06 Million | $-24.36 Million | -0.442x | -31.31% |
| 2021-12-31 | $62.80 Million | $-21.16 Million | -0.337x | +32.18% |
| 2020-12-31 | $44.22 Million | $-21.97 Million | -0.497x | +21.96% |
| 2019-12-31 | $23.65 Million | $-15.05 Million | -0.637x | +86.75% |
| 2018-12-31 | $4.93 Million | $-23.70 Million | -4.803x | -20.86% |
| 2017-12-31 | $7.19 Million | $-28.59 Million | -3.974x | -217.97% |
| 2016-12-31 | $17.81 Million | $-22.27 Million | -1.250x | -239.34% |
| 2015-12-31 | $34.01 Million | $-12.53 Million | -0.368x | +78.82% |
| 2014-12-31 | $3.63 Million | $-6.32 Million | -1.739x | -293.32% |
| 2013-12-31 | $-4.02 Million | $-3.62 Million | 0.900x | -81.21% |
| 2012-12-31 | $-475.38K | $-2.28 Million | 4.788x | +194.03% |
| 2011-12-31 | $1.24 Million | $-6.30 Million | -5.092x | -907.15% |
| 2010-12-31 | $7.26 Million | $-3.67 Million | -0.506x | -446.48% |
| 2009-12-31 | $-14.71 Million | $-2.15 Million | 0.146x | -57.32% |
| 2008-12-31 | $-12.03 Million | $-4.11 Million | 0.342x | -- |